About this Research Topic
The view that epigenetic and transcriptional alterations in the human genome may play a direct role in development and progression of cancer and resistance to treatment has been gradually consolidated during the last decade. Its potential applicability to cancer diagnosis and prognosis has also strongly emerged. However, our understanding of these alterations in the ambit of gynecologic cancers has remained relatively poorly understood. In this Topic, we encourage the submission of studies that address the influence of epigenetic and transcriptional events to the different phases of the disease in ovarian, cervical, uterine, vaginal, and vulvar cancers. We will consider reports that study DNA methylation and histone marks, as well as the study of their protein modifiers (readers, writers, or erasers). We will also welcome studies about the role of any type of short and long non-coding RNA (ncRNAs), as well as the involvement of transcription factors and cofactors. We specially encourage studies employed at genome-wide scale (epigenomic, transcriptomic, or cistromic analyses), but we will gladly accept submissions focused at locus-specific scale. We also encourage submission of studies that address pharmacologic inhibition of any of these regulatory processes. With this Topic, our goal is to raise awareness of the importance that these aspects may play in development and progression of gynecologic cancers and drug resistance, and to facilitate the coordinated publication of these studies to advance as quickly as possible in our understanding of this important field. We request that in addition to conceptually align with the proposed Topic, all submitted works should follow the highest quality excellence.
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.